What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 24 months?
One-OffHealth & MedicineScience1mo
Manifold MarketsNo KYCVerified resolution dataFairly calibratedData quality warningSource data degraded
Data as of Oct 25, 2026, 6:45 PM UTC · policy pm-quality-4
Current community forecast70-79% 38.7%Leader of 7 outcomes
Forecasters
14
Question type
multiple choice
Methodology
Play-money forecasting platform
Source type
Forecast
7d Change
+16.9 pts
Market data
Updated 5 hours ago
StaleMar 15, 24, 9:17 PM UTCDec 2, 26, 7:59 AM UTC
Trends
Related Markets
Related questions for context, not a comparison of equivalent contracts.
What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWill molecular jackhammers have at least 50% tumour-free efficacy in Phase 2 clinical trials?
Manifold MarketsWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
KalshiHow many human screwworm cases will be reported in the United States in 2026?
KalshiWhen will Beam Therapeutics submit a BLA for Risto-cel?
KalshiWill WHO classify the current hantavirus outbreak as a Public Health Emergency of International Concern by end of 2026?
Manifold MarketsRules
The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.
- Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
- Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2025).
- Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
- 1Day Sooner has an R21 Status Report available here that may be useful.
- More malaria-related questions can be found on our Manifold account here.
